Key figures

 

 

SEK million

 

2018

 

2017

 

2016

 

2015

 

2014

Net revenues

783.1

643.7

705.9

646.2

570.3

whereof Zubsolv US net revenue

621.5

485.8

481.8

416.7

228.0

Cost of goods sold

–171.8

–164.4

–149.6

–150.2

–107.4

Operating expenses

–515.6

–421.9

–584.4

–676.6

–487.9

EBIT

95.8

57.4

51.7

–180.6

–25.0

EBIT margin, %

12.2

8.9

7.3

–27.9

–4.4

US EBIT

198.3

73.7

21.4

–109.1

–100.4

US EBIT marginal, %

31.9

15.2

4.4

–26.2

–44.0

EBITDA

116.6

78.2

73.1

–99.9

–12.5

Earnings per share, before dilution, SEK

3.99

0.67

0.84

–6.09

–1.70

Earnings per share, after dilution, SEK

3.93

0.67

0.84

–6.09

–1.70

Cash flow from operating activities

242.0

146.6

156.2

–109.2

–487.3

Cash and cash equivalents

589.8

327.9

282.4

198.1

284.5

 

1 One of the products, Diabact, was divested when the subsidiary Kibion was sold in 2015